$0.28
+0.05
(+22.27%)▲
Live
17.86%
Downside
Day's Volatility :17.86%
Upside
0.0%
26.61%
Downside
52 Weeks Volatility :98.55%
Upside
98.03%
Period | Scisparc Ltd | Index (Russel 2000) |
---|---|---|
3 Months | -65.94% | 0.0% |
6 Months | -81.21% | 0.0% |
1 Year | -95.86% | 0.0% |
3 Years | -99.87% | -23.0% |
Market Capitalization | 2.4M |
Book Value | $10.77 |
Earnings Per Share (EPS) | -14.43 |
Profit Margin | -177.91% |
Operating Margin TTM | -309.37% |
Return On Assets TTM | -33.12% |
Return On Equity TTM | -73.37% |
Revenue TTM | 2.9M |
Revenue Per Share TTM | 7.06 |
Quarterly Revenue Growth YOY | -32.7% |
Gross Profit TTM | 1.0M |
EBITDA | -5.3M |
Diluted Eps TTM | -14.43 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | 0.0 |
EPS Estimate Next Year | 0.0 |
EPS Estimate Current Quarter | 0.0 |
EPS Estimate Next Quarter | 0.0 |
FY18 | Y/Y Change | |
---|---|---|
Revenue | 838.0K | ↑ 72.07% |
Net Income | -8.5M | ↑ 36.5% |
Net Profit Margin | -1.0K% | ↑ 265.08% |
FY19 | Y/Y Change | |
---|---|---|
Revenue | 498.0K | ↓ 40.57% |
Net Income | -5.4M | ↓ 37.09% |
Net Profit Margin | -1.1K% | ↓ 59.65% |
FY20 | Y/Y Change | |
---|---|---|
Revenue | 550.0K | ↑ 10.44% |
Net Income | -3.5M | ↓ 34.6% |
Net Profit Margin | -637.64% | ↑ 439.07% |
FY21 | Y/Y Change | |
---|---|---|
Revenue | 1.1M | ↑ 94.36% |
Net Income | -5.8M | ↑ 65.41% |
Net Profit Margin | -542.66% | ↑ 94.98% |
FY22 | Y/Y Change | |
---|---|---|
Revenue | 1.3M | ↑ 26.01% |
Net Income | -2.6M | ↓ 55.32% |
Net Profit Margin | -192.43% | ↑ 350.23% |
FY23 | Y/Y Change | |
---|---|---|
Revenue | 2.9M | ↑ 113.73% |
Net Income | -5.1M | ↑ 97.61% |
Net Profit Margin | -177.91% | ↑ 14.52% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Revenue | 1.3M | - |
Net Income | 3.2M | - |
Net Profit Margin | 235.12% | - |
Q2 FY23 | Q/Q Change | |
---|---|---|
Revenue | 2.0M | ↑ 46.4% |
Net Income | -2.9M | ↓ 190.94% |
Net Profit Margin | -146.04% | ↓ 381.16% |
Q1 FY24 | Q/Q Change | |
---|---|---|
Revenue | 907.0K | ↓ 54.01% |
Net Income | -2.2M | ↓ 22.15% |
Net Profit Margin | -247.19% | ↓ 101.15% |
FY18 | Y/Y Change | |
---|---|---|
Total Assets | 4.6M | ↓ 52.33% |
Total Liabilities | 4.5M | ↑ 280.88% |
FY19 | Y/Y Change | |
---|---|---|
Total Assets | 1.2M | ↓ 74.69% |
Total Liabilities | 1.1M | ↓ 74.57% |
FY20 | Y/Y Change | |
---|---|---|
Total Assets | 2.6M | ↑ 121.92% |
Total Liabilities | 1.1M | ↓ 0.79% |
FY21 | Y/Y Change | |
---|---|---|
Total Assets | 9.9M | ↑ 287.19% |
Total Liabilities | 1.8M | ↑ 56.94% |
FY22 | Y/Y Change | |
---|---|---|
Total Assets | 10.6M | ↑ 6.95% |
Total Liabilities | 4.2M | ↑ 134.14% |
FY23 | Y/Y Change | |
---|---|---|
Total Assets | 11.2M | ↑ 5.44% |
Total Liabilities | 1.6M | ↓ 61.62% |
Q3 FY22 | Q/Q Change | |
---|---|---|
Total Assets | 22.5M | ↑ 55.69% |
Total Liabilities | 14.1M | ↑ 23.89% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Total Assets | 10.6M | ↓ 52.77% |
Total Liabilities | 4.2M | ↓ 70.54% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 10.6M | ↑ 0.0% |
Total Liabilities | 4.2M | ↑ 0.0% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 9.9M | ↓ 6.72% |
Total Liabilities | 3.1M | ↓ 25.07% |
Q4 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 11.2M | ↑ 13.04% |
Total Liabilities | 1.6M | ↓ 48.78% |
Q1 FY24 | Q/Q Change | |
---|---|---|
Total Assets | 11.2M | ↑ 0.0% |
Total Liabilities | 1.6M | ↑ 0.0% |
FY18 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -7.1M | ↑ 55.75% |
Investing Cash Flow | -2.1M | ↑ 3850.94% |
Financing Cash Flow | 1.5M | ↓ 88.34% |
FY19 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -4.7M | ↓ 34.16% |
Investing Cash Flow | 1.3M | ↓ 160.55% |
Financing Cash Flow | 2.8M | ↑ 82.55% |
FY20 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -4.3M | ↓ 8.28% |
Investing Cash Flow | 24.0K | ↓ 98.11% |
Financing Cash Flow | 5.4M | ↑ 91.12% |
FY21 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -5.1M | ↑ 17.51% |
Investing Cash Flow | -70.0K | ↓ 391.67% |
Financing Cash Flow | 10.1M | ↑ 87.72% |
FY22 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -7.9M | ↑ 56.43% |
Investing Cash Flow | -7.1M | ↑ 10020.0% |
Financing Cash Flow | 11.7M | ↑ 16.3% |
Q3 FY22 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -2.9M | ↑ 30.92% |
Investing Cash Flow | -3.2M | - |
Financing Cash Flow | 1.4M | ↓ 84.75% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -2.9M | ↑ 0.0% |
Investing Cash Flow | -3.2M | ↑ 0.0% |
Financing Cash Flow | 1.4M | ↑ 0.0% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -5.7M | ↑ 100.0% |
Investing Cash Flow | -535.5K | ↓ 83.2% |
Financing Cash Flow | 2.7M | ↑ 100.0% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -3.2M | ↓ 43.57% |
Investing Cash Flow | -535.5K | ↑ 0.0% |
Financing Cash Flow | 2.8M | ↑ 2.82% |
Sell
Neutral
Buy
Scisparc Ltd is currently in a favorable trading position ( BUY ) according to technical analysis indicators.
Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
---|---|---|---|---|---|
Scisparc Ltd | -13.18% | -81.21% | -95.86% | -99.87% | -99.87% |
Regeneron Pharmaceuticals, Inc. | -9.28% | 10.06% | 24.53% | 74.0% | 232.45% |
Novo Nordisk A/s | -4.54% | -5.72% | 21.59% | 126.2% | 349.01% |
Alnylam Pharmaceuticals, Inc. | 8.87% | 102.98% | 82.67% | 44.83% | 241.09% |
Vertex Pharmaceuticals Incorporated | 5.0% | 20.77% | 31.37% | 158.16% | 163.17% |
Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
---|---|---|---|---|---|---|---|---|
Scisparc Ltd | 0.0 | NA | NA | 0.0 | -0.73 | -0.33 | NA | 10.77 |
Regeneron Pharmaceuticals, Inc. | 26.41 | 26.41 | 1.37 | 44.9 | 0.17 | 0.08 | NA | 261.41 |
Novo Nordisk A/s | 40.21 | 40.21 | 1.81 | 3.36 | 0.89 | 0.23 | 0.01 | 25.24 |
Alnylam Pharmaceuticals, Inc. | NA | NA | -0.49 | -2.42 | -15.01 | 0.02 | NA | -0.02 |
Vertex Pharmaceuticals Incorporated | 32.84 | NA | 0.59 | 0.18 | -0.03 | 0.13 | NA | 57.26 |
Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
---|---|---|---|---|---|
Scisparc Ltd | NA | $2.4M | -99.87% | 0.0 | -177.91% |
Regeneron Pharmaceuticals, Inc. | Buy | $110.0B | 232.45% | 26.41 | 32.04% |
Novo Nordisk A/s | Buy | $529.8B | 349.01% | 40.21 | 34.84% |
Alnylam Pharmaceuticals, Inc. | Buy | $38.1B | 241.09% | NA | -3.11% |
Vertex Pharmaceuticals Incorporated | Buy | $128.7B | 163.17% | 32.84 | -4.74% |
Insights on Scisparc Ltd
In the last 1 year, Alnylam Pharmaceuticals, Inc. has given 82.9% return, outperforming this stock by 178.5%
Renaissance Technologies Corp
Citadel Advisors Llc
Two Sigma Investments LLC
Rhumbline Advisers
UBS Group AG
Organization | Scisparc Ltd |
Employees | 3 |
CEO | Mr. Oz Adler CPA |
Industry | Miscellaneous |
Jpmorgan Betabuilders 1-5 Year Us Aggregate Bd Etf
$0.28
+22.27%
Invesco Bulletshares 2025 Hi
$0.28
+22.27%
Schwab International Dividend Equity Etf
$0.28
+22.27%
Innovator Intl Developed 10 Buffer Etf - Quarterly
$0.28
+22.27%
Lightpath Technologies Inc
$0.28
+22.27%
Vaneck Vectors Global Alternative Energy Etf
$0.28
+22.27%
First Trust Flexible Municipal High Income Etf
$0.28
+22.27%
Drx Dly Reg Bank Bull 3x
$0.28
+22.27%
Graniteshares 2x Long Pltr Daily Etf
$0.28
+22.27%